Aesica Pharmaceuticals Relocates Services to Queenborough

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016
Volume 12
Issue 2

Aesica Pharmaceuticals, a global pharmaceutical contract development and manufacturing organization (CDMO), announced the strategic relocation of development and clinical manufacturing services from Nottingham to Queenborough. The new development center at Queenborough has more than twice the capacity of the existing one in Nottingham.

Aesica Pharmaceuticals, a global pharmaceutical contract development and manufacturing organization (CDMO), announced the strategic relocation of development and clinical manufacturing services from Nottingham to Queenborough. The new development center at Queenborough has more than twice the capacity of the existing one in Nottingham.

According to a Jan. 19, 2016 press announcement from the company, Aesica will now provide full manufacturing and development services at its Queenborough site with the addition of a new development center. From Queenborough, the company now provides API production, formulation development, and clinical manufacture through to commercial-scale product manufacturing.

The new development center will be able to handle potent and controlled drugs, which mirror the commercial offering from Queenborough. The company will also still offer semi-solid development and inhalation services. 

Source: Aesica Pharmaceuticals

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content